Bisphosphonates and lifespan

Area of Science:

• Pharmacology
• Gerontology
• Oncology

Background:

• Bisphosphonates are primary treatments for osteoporosis, reducing fracture rates by inhibiting bone remodeling.
• They also mitigate skeletal complications in cancer patients, including bone metastases.
• An unexpected survival benefit observed in the zoledronate hip fracture trial (HORIZON) sparked interest in their lifespan-extending potential.

Purpose of the Study:

• To review the clinical evidence for bisphosphonates' effects on mortality.
• To explore potential survival benefits in osteoporosis and non-osteoporosis settings.
• To discuss proposed mechanisms underlying observed survival benefits.

Main Methods:

• Literature review of randomized controlled trials and observational studies.
• Analysis of bisphosphonate efficacy in osteoporosis, cancer, intensive care, and cardiovascular disease.
• Synthesis of proposed biological mechanisms for survival effects.

Main Results:

• Bisphosphonates demonstrate efficacy in reducing fractures and skeletal complications.
• Evidence suggests a potential survival benefit in specific patient populations, including post-hip fracture.
• Mechanisms may involve anti-inflammatory, anti-cancer, or direct cellular effects.

Conclusions:

• Bisphosphonates show promise beyond skeletal health, with potential mortality benefits.
• Further research is warranted to elucidate mechanisms and confirm efficacy across diverse conditions.
• Clinical application may expand to include lifespan extension strategies.